Cat. #153269
Anti-deltaEGFR recombinant [DH8.3] rAb
Cat. #: 153269
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Epidermal growth factor. Truncated EGF receptor (RGFR typeIII/EGFRvIII/deltaEGFR). Recognises an EGFR with truncated extracellular domain, present on human tumours.
Class: Recombinant
Application: ELISA ; FACS ; IHC ; IP ; WB
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Bill Gullick
Institute: Absolute Antibody ; Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-deltaEGFR recombinant [DH8.3] rAb
- Alternate name: EGFRvIII, Avian erythroblastic leukemia viral (v erb b) oncogene homolog, Cell growth inhibiting protein 4, Cell proliferation inducing protein 61, EGF R, EGFR, Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian), Epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 1, ERBB, ERBB1, Errp, HER1, mENA, NISBD2, Oncogen ERBB, PIG61, Proto-onc...
- Clone: DH8.3
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Cell signalling pathway: EGFR
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; FACS ; IHC ; IP ; WB
- Description: Recombinant monoclonal antibody directed against deltaEGFR, also known as EGFRvIII, a mutated form of EGFR, typically found in brain tumours, with use in radiolabelled tumour imaging and potentially therapeutic targeting against deltaEGFR tumours.
Background and Research Application
Epidermal growth factor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type EGFR is amplified in a number of cancers, and several mutant forms of the EGFR coding ... - Immunogen: Synthetic peptide corresponding to the junctional region of the truncated receptor LEEKKGNYVVTDHC,conjugated to keyhole limpet haemcyanin.
- Immunogen uniprot id: P00533
- Isotype: IgG1
Target Details
- Target: Epidermal growth factor. Truncated EGF receptor (RGFR typeIII/EGFRvIII/deltaEGFR). Recognises an EGFR with truncated extracellular domain, present on human tumours.
- Target alternate names: EGFRvIII
- Target background: Recombinant monoclonal antibody directed against deltaEGFR, also known as EGFRvIII, a mutated form of EGFR, typically found in brain tumours, with use in radiolabelled tumour imaging and potentially therapeutic targeting against deltaEGFR tumours.
Background and Research Application
Epidermal growth factor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type EGFR is amplified in a number of cancers, and several mutant forms of the EGFR coding ...
Applications
- Application: ELISA ; FACS ; IHC ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Shipping at 4° C
References
- Original hybridoma first published in: Hills et al. 1995. Int J Cancer. 63(4):537-43. PMID: 7591264.
- GenĂler et al. 2016. Oncoimmunology. 5(4):e1119354. PMID: 27141401.
- Feng et al. 2014. J Clin Invest. 124(9):3741-56. PMID: 25061874.
